PREVIEW
When the primary tumor site cannot be identified in patients with metastatic carcinoma, the survival rate is discouragingly low. In such cases, recognition of subgroups of patients who have a better chance of long-term survival is critical. In this article, Drs Brigden and Murray present a detailed approach to diagnosis and management.